Jeff M. Kucharski

Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor

P. Zarrinkar, K. Yu, D. Brehmer, 2018, Cell.

Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State.

U. Peters, M. Patricelli, Yi Liu, 2016, Cancer discovery.

Abstract A171: A potent and selective PI3K inhibitor, INK1117, targets human cancers harboring oncogenic PIK3CA mutations.

Shunyou Wang, Katrina Chan, C. Rommel, 2011 .